Dompe's Private Power
Milan's Dompé Biotec is arguably Italy's leading marketer of biotechnology products. The wholly-owned subsidiary of Dompé Farmaceutici SPA gained access to three early products of biotechnology by allying with the large multinational firms that held European rights to them. But the privately held Italian firm has since made a point of directly pursuing American biotech companies, because they have what it wants: innovative treatments for specific medical conditions. But even the most carefully considered in-licensing deals won't help Dompé grow as fast as its owners would like. The firm, now intent on expanding its reach beyond Italy, hopes its past marketing experience will attract new partners.
You may also be interested in...
An enormous recall of more than 314 million device units proved to be a headache for industry in the first quarter of 2020. But on a slightly brighter note, manufacturers initiated 260 recalls in the first quarter, a 6% decline from 2019’s fourth quarter tally of 277. Check out our Q1 recalls infographic.
Acutus Medical Inks Marketing Deal With Biotronik; Mapping Its Way To Electrophysiologists Outside US
Biotronik will help Acutus to bring its cardiac mapping software and guidance system to electrophysiologists worldwide.
Manufacturers Should Map Processes, Bolster Quality Culture To Tackle Data Integrity Problems in The Microbiology Lab
To reduce the opportunity for data integrity failures in the microbiology lab, manufacturers should map out the workflow so that activities and expectations for employees are clearly spelled out. Having formalized processes will ensure that employees don’t cut corners.